Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Lewy Body Disease 1Congenital Hyperinsulinism 1Brain Neoplasms 1

Interventions

Everolimus 6lutetium Lu 177 dotatate 5lanreotide 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Capecitabine 3surufatinib 2fluorodopa F 18 2Introns 2telotristat ethyl 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Temozolomide 1Sunitinib 1Specimen Handling 1Somatostatin 1Serotonin 1Salts 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Leucovorin 1Interferon alpha-2 1Immunoglobulin G 1Ga(III)-DOTATOC 1Furosemide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neuroendocrine Tumors × 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡